MetaCap

Kalaris Therapeutics (KLRS) vs Pelthos Therapeutics (PTHS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pelthos Therapeutics (PTHS) has outperformed Kalaris Therapeutics (KLRS) over the past year, losing 74.9% versus a loss of 81.7%. Kalaris Therapeutics is the larger company by market cap ($30.5 million vs $25.1 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KLRS-81.74%PTHS-74.88%
+64%-13%-89%
Nov 21, 20251 yearNov 20, 2026
KLRS-92.05%PTHS-86.71%
+43%-28%-98%
Feb 12, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KLRS versus PTHS key metrics
MetricKLRSPTHS
Share price$1.28$6.38
Market cap$30.47M$25.08M
1-day change-5.19%-8.73%
YTD return-84.83%-79.42%
1-year return-81.74%-74.88%
5-year return-99.70%—
EPS (TTM)$-1.84$-23.86
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$16.80M
Net income (latest FY)$-43.44M$-43.32M
Gross margin—76.25%
Operating margin—-193.09%
Net margin—-257.93%
52-week high$11.88$31.62
52-week low$1.25$6.02
Distance from 52-week high-89.23%-79.82%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1361.72%+732.92%
Average volume77.37K54.38K
Shares outstanding23.80M3.93M
Employees2092
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Kalaris Therapeutics

KLRS stock →

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees

About Pelthos Therapeutics

PTHS stock →

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees

KLRS vs PTHS FAQ

Which is bigger, Kalaris Therapeutics or Pelthos Therapeutics?

Kalaris Therapeutics (KLRS) is larger, with a market capitalization of $30.47M compared with $25.08M for Pelthos Therapeutics (PTHS).

Which stock has performed better over the past year, KLRS or PTHS?

PTHS returned -74.88% over the past 12 months, compared with -81.74% for KLRS (price return, excluding dividends). Past performance does not predict future results.

Are Kalaris Therapeutics and Pelthos Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons